sample_id stringlengths 11 11 | clinical_text stringlengths 18 347 | category stringclasses 5
values | subcategory stringclasses 20
values | difficulty stringclasses 4
values | drug_mentions listlengths 1 14 | regimen_mentions listlengths 0 2 | num_drugs int64 1 8 | note_type stringclasses 10
values |
|---|---|---|---|---|---|---|---|---|
ONCORX-0001 | The patient was started on Abemaciclib. | C1_CORE_MED_EXTRACTION | C1.1_single_drug_simple | Easy | [
{
"drug_surface": "Abemaciclib",
"drug_normalized": "Abemaciclib",
"status": "current",
"negated": false,
"allergy": false,
"uncertain": false,
"evidence_type": "explicit_surface",
"start_char": 27,
"end_char": 38
}
] | [] | 1 | progress_note |
ONCORX-0002 | Per oncology, continue Pembrolizumab. | C1_CORE_MED_EXTRACTION | C1.1_single_drug_simple | Easy | [
{
"drug_surface": "Pembrolizumab",
"drug_normalized": "Pembrolizumab",
"status": "current",
"negated": false,
"allergy": false,
"uncertain": false,
"evidence_type": "explicit_surface",
"start_char": 23,
"end_char": 36
}
] | [] | 1 | progress_note |
ONCORX-0003 | Recommend initiation of Chlorambucil. | C1_CORE_MED_EXTRACTION | C1.1_single_drug_simple | Easy | [
{
"drug_surface": "Chlorambucil",
"drug_normalized": "Chlorambucil",
"status": "current",
"negated": false,
"allergy": false,
"uncertain": false,
"evidence_type": "explicit_surface",
"start_char": 24,
"end_char": 36
}
] | [] | 1 | treatment_plan |
ONCORX-0004 | Current therapy: Capecitabine. | C1_CORE_MED_EXTRACTION | C1.1_single_drug_simple | Easy | [
{
"drug_surface": "Capecitabine",
"drug_normalized": "Capecitabine",
"status": "current",
"negated": false,
"allergy": false,
"uncertain": false,
"evidence_type": "explicit_surface",
"start_char": 17,
"end_char": 29
}
] | [] | 1 | treatment_plan |
ONCORX-0006 | Treatment: Niraparib. | C1_CORE_MED_EXTRACTION | C1.1_single_drug_simple | Easy | [
{
"drug_surface": "Niraparib",
"drug_normalized": "Niraparib",
"status": "current",
"negated": false,
"allergy": false,
"uncertain": false,
"evidence_type": "explicit_surface",
"start_char": 11,
"end_char": 20
}
] | [] | 1 | progress_note |
ONCORX-0008 | Oncology recommends Carmustine. | C1_CORE_MED_EXTRACTION | C1.1_single_drug_simple | Easy | [
{
"drug_surface": "Carmustine",
"drug_normalized": "Carmustine",
"status": "current",
"negated": false,
"allergy": false,
"uncertain": false,
"evidence_type": "explicit_surface",
"start_char": 20,
"end_char": 30
}
] | [] | 1 | treatment_plan |
ONCORX-0010 | Home medications include Leuprolide. | C1_CORE_MED_EXTRACTION | C1.1_single_drug_simple | Easy | [
{
"drug_surface": "Leuprolide",
"drug_normalized": "Leuprolide",
"status": "current",
"negated": false,
"allergy": false,
"uncertain": false,
"evidence_type": "explicit_surface",
"start_char": 25,
"end_char": 35
}
] | [] | 1 | treatment_plan |
ONCORX-0011 | Treatment: Ixazomib. | C1_CORE_MED_EXTRACTION | C1.1_single_drug_simple | Easy | [
{
"drug_surface": "Ixazomib",
"drug_normalized": "Ixazomib",
"status": "current",
"negated": false,
"allergy": false,
"uncertain": false,
"evidence_type": "explicit_surface",
"start_char": 11,
"end_char": 19
}
] | [] | 1 | progress_note |
ONCORX-0012 | Please continue Sunitinib. | C1_CORE_MED_EXTRACTION | C1.1_single_drug_simple | Easy | [
{
"drug_surface": "Sunitinib",
"drug_normalized": "Sunitinib",
"status": "current",
"negated": false,
"allergy": false,
"uncertain": false,
"evidence_type": "explicit_surface",
"start_char": 16,
"end_char": 25
}
] | [] | 1 | oncology_consult |
ONCORX-0013 | Currently maintained on Trastuzumab. | C1_CORE_MED_EXTRACTION | C1.1_single_drug_simple | Easy | [
{
"drug_surface": "Trastuzumab",
"drug_normalized": "Trastuzumab",
"status": "current",
"negated": false,
"allergy": false,
"uncertain": false,
"evidence_type": "explicit_surface",
"start_char": 24,
"end_char": 35
}
] | [] | 1 | progress_note |
ONCORX-0014 | Initiate therapy with Durvalumab as discussed. | C1_CORE_MED_EXTRACTION | C1.1_single_drug_simple | Easy | [
{
"drug_surface": "Durvalumab",
"drug_normalized": "Durvalumab",
"status": "current",
"negated": false,
"allergy": false,
"uncertain": false,
"evidence_type": "explicit_surface",
"start_char": 22,
"end_char": 32
}
] | [] | 1 | progress_note |
ONCORX-0015 | Treatment: Exemestane. | C1_CORE_MED_EXTRACTION | C1.1_single_drug_simple | Easy | [
{
"drug_surface": "Exemestane",
"drug_normalized": "Exemestane",
"status": "current",
"negated": false,
"allergy": false,
"uncertain": false,
"evidence_type": "explicit_surface",
"start_char": 11,
"end_char": 21
}
] | [] | 1 | oncology_consult |
ONCORX-0016 | Recommend initiation of Mercaptopurine. | C1_CORE_MED_EXTRACTION | C1.1_single_drug_simple | Easy | [
{
"drug_surface": "Mercaptopurine",
"drug_normalized": "Mercaptopurine",
"status": "current",
"negated": false,
"allergy": false,
"uncertain": false,
"evidence_type": "explicit_surface",
"start_char": 24,
"end_char": 38
}
] | [] | 1 | progress_note |
ONCORX-0017 | Assessment/Plan: Durvalumab for treatment. | C1_CORE_MED_EXTRACTION | C1.1_single_drug_simple | Easy | [
{
"drug_surface": "Durvalumab",
"drug_normalized": "Durvalumab",
"status": "current",
"negated": false,
"allergy": false,
"uncertain": false,
"evidence_type": "explicit_surface",
"start_char": 17,
"end_char": 27
}
] | [] | 1 | progress_note |
ONCORX-0018 | Pt currently receiving Bendamustine. | C1_CORE_MED_EXTRACTION | C1.1_single_drug_simple | Easy | [
{
"drug_surface": "Bendamustine",
"drug_normalized": "Bendamustine",
"status": "current",
"negated": false,
"allergy": false,
"uncertain": false,
"evidence_type": "explicit_surface",
"start_char": 23,
"end_char": 35
}
] | [] | 1 | progress_note |
ONCORX-0019 | Currently maintained on Gefitinib. | C1_CORE_MED_EXTRACTION | C1.1_single_drug_simple | Easy | [
{
"drug_surface": "Gefitinib",
"drug_normalized": "Gefitinib",
"status": "current",
"negated": false,
"allergy": false,
"uncertain": false,
"evidence_type": "explicit_surface",
"start_char": 24,
"end_char": 33
}
] | [] | 1 | oncology_consult |
ONCORX-0020 | Per oncology, continue Everolimus. | C1_CORE_MED_EXTRACTION | C1.1_single_drug_simple | Easy | [
{
"drug_surface": "Everolimus",
"drug_normalized": "Everolimus",
"status": "current",
"negated": false,
"allergy": false,
"uncertain": false,
"evidence_type": "explicit_surface",
"start_char": 23,
"end_char": 33
}
] | [] | 1 | progress_note |
ONCORX-0021 | Medications: Degarelix. | C1_CORE_MED_EXTRACTION | C1.1_single_drug_simple | Easy | [
{
"drug_surface": "Degarelix",
"drug_normalized": "Degarelix",
"status": "current",
"negated": false,
"allergy": false,
"uncertain": false,
"evidence_type": "explicit_surface",
"start_char": 13,
"end_char": 22
}
] | [] | 1 | treatment_plan |
ONCORX-0022 | The patient is scheduled to receive Cytarabine. | C1_CORE_MED_EXTRACTION | C1.1_single_drug_simple | Easy | [
{
"drug_surface": "Cytarabine",
"drug_normalized": "Cytarabine",
"status": "current",
"negated": false,
"allergy": false,
"uncertain": false,
"evidence_type": "explicit_surface",
"start_char": 36,
"end_char": 46
}
] | [] | 1 | oncology_consult |
ONCORX-0024 | Home medications include Ramucirumab. | C1_CORE_MED_EXTRACTION | C1.1_single_drug_simple | Easy | [
{
"drug_surface": "Ramucirumab",
"drug_normalized": "Ramucirumab",
"status": "current",
"negated": false,
"allergy": false,
"uncertain": false,
"evidence_type": "explicit_surface",
"start_char": 25,
"end_char": 36
}
] | [] | 1 | treatment_plan |
ONCORX-0025 | Currently maintained on Dexamethasone. | C1_CORE_MED_EXTRACTION | C1.1_single_drug_simple | Easy | [
{
"drug_surface": "Dexamethasone",
"drug_normalized": "Dexamethasone",
"status": "current",
"negated": false,
"allergy": false,
"uncertain": false,
"evidence_type": "explicit_surface",
"start_char": 24,
"end_char": 37
}
] | [] | 1 | oncology_consult |
ONCORX-0027 | Continue Idarubicin as previously prescribed. | C1_CORE_MED_EXTRACTION | C1.1_single_drug_simple | Easy | [
{
"drug_surface": "Idarubicin",
"drug_normalized": "Idarubicin",
"status": "current",
"negated": false,
"allergy": false,
"uncertain": false,
"evidence_type": "explicit_surface",
"start_char": 9,
"end_char": 19
}
] | [] | 1 | treatment_plan |
ONCORX-0028 | Resume Carmustine after hold period. | C1_CORE_MED_EXTRACTION | C1.1_single_drug_simple | Easy | [
{
"drug_surface": "Carmustine",
"drug_normalized": "Carmustine",
"status": "current",
"negated": false,
"allergy": false,
"uncertain": false,
"evidence_type": "explicit_surface",
"start_char": 7,
"end_char": 17
}
] | [] | 1 | oncology_consult |
ONCORX-0029 | Currently maintained on Ifosfamide. | C1_CORE_MED_EXTRACTION | C1.1_single_drug_simple | Easy | [
{
"drug_surface": "Ifosfamide",
"drug_normalized": "Ifosfamide",
"status": "current",
"negated": false,
"allergy": false,
"uncertain": false,
"evidence_type": "explicit_surface",
"start_char": 24,
"end_char": 34
}
] | [] | 1 | progress_note |
ONCORX-0030 | The patient was started on Elotuzumab. | C1_CORE_MED_EXTRACTION | C1.1_single_drug_simple | Easy | [
{
"drug_surface": "Elotuzumab",
"drug_normalized": "Elotuzumab",
"status": "current",
"negated": false,
"allergy": false,
"uncertain": false,
"evidence_type": "explicit_surface",
"start_char": 27,
"end_char": 37
}
] | [] | 1 | oncology_consult |
ONCORX-0031 | Medications: Mercaptopurine. | C1_CORE_MED_EXTRACTION | C1.1_single_drug_simple | Easy | [
{
"drug_surface": "Mercaptopurine",
"drug_normalized": "Mercaptopurine",
"status": "current",
"negated": false,
"allergy": false,
"uncertain": false,
"evidence_type": "explicit_surface",
"start_char": 13,
"end_char": 27
}
] | [] | 1 | treatment_plan |
ONCORX-0032 | Patient seen in clinic today, currently on Ramucirumab. | C1_CORE_MED_EXTRACTION | C1.1_single_drug_simple | Easy | [
{
"drug_surface": "Ramucirumab",
"drug_normalized": "Ramucirumab",
"status": "current",
"negated": false,
"allergy": false,
"uncertain": false,
"evidence_type": "explicit_surface",
"start_char": 43,
"end_char": 54
}
] | [] | 1 | progress_note |
ONCORX-0033 | Patient seen in clinic today, currently on Osimertinib. | C1_CORE_MED_EXTRACTION | C1.1_single_drug_simple | Easy | [
{
"drug_surface": "Osimertinib",
"drug_normalized": "Osimertinib",
"status": "current",
"negated": false,
"allergy": false,
"uncertain": false,
"evidence_type": "explicit_surface",
"start_char": 43,
"end_char": 54
}
] | [] | 1 | progress_note |
ONCORX-0034 | Per oncology, continue Darolutamide. | C1_CORE_MED_EXTRACTION | C1.1_single_drug_simple | Easy | [
{
"drug_surface": "Darolutamide",
"drug_normalized": "Darolutamide",
"status": "current",
"negated": false,
"allergy": false,
"uncertain": false,
"evidence_type": "explicit_surface",
"start_char": 23,
"end_char": 35
}
] | [] | 1 | treatment_plan |
ONCORX-0035 | Current therapy: Pegfilgrastim. | C1_CORE_MED_EXTRACTION | C1.1_single_drug_simple | Easy | [
{
"drug_surface": "Pegfilgrastim",
"drug_normalized": "Pegfilgrastim",
"status": "current",
"negated": false,
"allergy": false,
"uncertain": false,
"evidence_type": "explicit_surface",
"start_char": 17,
"end_char": 30
}
] | [] | 1 | treatment_plan |
ONCORX-0036 | Will proceed with Cyclophosphamide. | C1_CORE_MED_EXTRACTION | C1.1_single_drug_simple | Easy | [
{
"drug_surface": "Cyclophosphamide",
"drug_normalized": "Cyclophosphamide",
"status": "current",
"negated": false,
"allergy": false,
"uncertain": false,
"evidence_type": "explicit_surface",
"start_char": 18,
"end_char": 34
}
] | [] | 1 | treatment_plan |
ONCORX-0038 | Dacarbazine was administered during today's visit. | C1_CORE_MED_EXTRACTION | C1.1_single_drug_simple | Easy | [
{
"drug_surface": "Dacarbazine",
"drug_normalized": "Dacarbazine",
"status": "current",
"negated": false,
"allergy": false,
"uncertain": false,
"evidence_type": "explicit_surface",
"start_char": 0,
"end_char": 11
}
] | [] | 1 | oncology_consult |
ONCORX-0039 | Per oncology, continue Crizotinib. | C1_CORE_MED_EXTRACTION | C1.1_single_drug_simple | Easy | [
{
"drug_surface": "Crizotinib",
"drug_normalized": "Crizotinib",
"status": "current",
"negated": false,
"allergy": false,
"uncertain": false,
"evidence_type": "explicit_surface",
"start_char": 23,
"end_char": 33
}
] | [] | 1 | treatment_plan |
ONCORX-0041 | Assessment/Plan: Letrozole for treatment. | C1_CORE_MED_EXTRACTION | C1.1_single_drug_simple | Easy | [
{
"drug_surface": "Letrozole",
"drug_normalized": "Letrozole",
"status": "current",
"negated": false,
"allergy": false,
"uncertain": false,
"evidence_type": "explicit_surface",
"start_char": 17,
"end_char": 26
}
] | [] | 1 | progress_note |
ONCORX-0043 | Assessment/Plan: Trastuzumab for treatment. | C1_CORE_MED_EXTRACTION | C1.1_single_drug_simple | Easy | [
{
"drug_surface": "Trastuzumab",
"drug_normalized": "Trastuzumab",
"status": "current",
"negated": false,
"allergy": false,
"uncertain": false,
"evidence_type": "explicit_surface",
"start_char": 17,
"end_char": 28
}
] | [] | 1 | oncology_consult |
ONCORX-0045 | Please continue Azacitidine. | C1_CORE_MED_EXTRACTION | C1.1_single_drug_simple | Easy | [
{
"drug_surface": "Azacitidine",
"drug_normalized": "Azacitidine",
"status": "current",
"negated": false,
"allergy": false,
"uncertain": false,
"evidence_type": "explicit_surface",
"start_char": 16,
"end_char": 27
}
] | [] | 1 | treatment_plan |
ONCORX-0047 | Pt currently receiving Acalabrutinib. | C1_CORE_MED_EXTRACTION | C1.1_single_drug_simple | Easy | [
{
"drug_surface": "Acalabrutinib",
"drug_normalized": "Acalabrutinib",
"status": "current",
"negated": false,
"allergy": false,
"uncertain": false,
"evidence_type": "explicit_surface",
"start_char": 23,
"end_char": 36
}
] | [] | 1 | treatment_plan |
ONCORX-0048 | Recommend initiation of Pazopanib. | C1_CORE_MED_EXTRACTION | C1.1_single_drug_simple | Easy | [
{
"drug_surface": "Pazopanib",
"drug_normalized": "Pazopanib",
"status": "current",
"negated": false,
"allergy": false,
"uncertain": false,
"evidence_type": "explicit_surface",
"start_char": 24,
"end_char": 33
}
] | [] | 1 | oncology_consult |
ONCORX-0049 | Patient reports taking Methotrexate at home. | C1_CORE_MED_EXTRACTION | C1.1_single_drug_simple | Easy | [
{
"drug_surface": "Methotrexate",
"drug_normalized": "Methotrexate",
"status": "current",
"negated": false,
"allergy": false,
"uncertain": false,
"evidence_type": "explicit_surface",
"start_char": 23,
"end_char": 35
}
] | [] | 1 | treatment_plan |
ONCORX-0051 | Please continue Nivolumab. | C1_CORE_MED_EXTRACTION | C1.1_single_drug_simple | Easy | [
{
"drug_surface": "Nivolumab",
"drug_normalized": "Nivolumab",
"status": "current",
"negated": false,
"allergy": false,
"uncertain": false,
"evidence_type": "explicit_surface",
"start_char": 16,
"end_char": 25
}
] | [] | 1 | oncology_consult |
ONCORX-0052 | Please continue Prednisone. | C1_CORE_MED_EXTRACTION | C1.1_single_drug_simple | Easy | [
{
"drug_surface": "Prednisone",
"drug_normalized": "Prednisone",
"status": "current",
"negated": false,
"allergy": false,
"uncertain": false,
"evidence_type": "explicit_surface",
"start_char": 16,
"end_char": 26
}
] | [] | 1 | oncology_consult |
ONCORX-0053 | Patient reports taking Afatinib at home. | C1_CORE_MED_EXTRACTION | C1.1_single_drug_simple | Easy | [
{
"drug_surface": "Afatinib",
"drug_normalized": "Afatinib",
"status": "current",
"negated": false,
"allergy": false,
"uncertain": false,
"evidence_type": "explicit_surface",
"start_char": 23,
"end_char": 31
}
] | [] | 1 | progress_note |
ONCORX-0054 | Venetoclax initiated per protocol. | C1_CORE_MED_EXTRACTION | C1.1_single_drug_simple | Easy | [
{
"drug_surface": "Venetoclax",
"drug_normalized": "Venetoclax",
"status": "current",
"negated": false,
"allergy": false,
"uncertain": false,
"evidence_type": "explicit_surface",
"start_char": 0,
"end_char": 10
}
] | [] | 1 | progress_note |
ONCORX-0055 | Continue Atezolizumab as previously prescribed. | C1_CORE_MED_EXTRACTION | C1.1_single_drug_simple | Easy | [
{
"drug_surface": "Atezolizumab",
"drug_normalized": "Atezolizumab",
"status": "current",
"negated": false,
"allergy": false,
"uncertain": false,
"evidence_type": "explicit_surface",
"start_char": 9,
"end_char": 21
}
] | [] | 1 | progress_note |
ONCORX-0056 | Home medications include Vinblastine. | C1_CORE_MED_EXTRACTION | C1.1_single_drug_simple | Easy | [
{
"drug_surface": "Vinblastine",
"drug_normalized": "Vinblastine",
"status": "current",
"negated": false,
"allergy": false,
"uncertain": false,
"evidence_type": "explicit_surface",
"start_char": 25,
"end_char": 36
}
] | [] | 1 | progress_note |
ONCORX-0057 | Current therapy: Rituximab. | C1_CORE_MED_EXTRACTION | C1.1_single_drug_simple | Easy | [
{
"drug_surface": "Rituximab",
"drug_normalized": "Rituximab",
"status": "current",
"negated": false,
"allergy": false,
"uncertain": false,
"evidence_type": "explicit_surface",
"start_char": 17,
"end_char": 26
}
] | [] | 1 | oncology_consult |
ONCORX-0059 | Will proceed with Crizotinib. | C1_CORE_MED_EXTRACTION | C1.1_single_drug_simple | Easy | [
{
"drug_surface": "Crizotinib",
"drug_normalized": "Crizotinib",
"status": "current",
"negated": false,
"allergy": false,
"uncertain": false,
"evidence_type": "explicit_surface",
"start_char": 18,
"end_char": 28
}
] | [] | 1 | oncology_consult |
ONCORX-0060 | Per oncology, continue Bortezomib. | C1_CORE_MED_EXTRACTION | C1.1_single_drug_simple | Easy | [
{
"drug_surface": "Bortezomib",
"drug_normalized": "Bortezomib",
"status": "current",
"negated": false,
"allergy": false,
"uncertain": false,
"evidence_type": "explicit_surface",
"start_char": 23,
"end_char": 33
}
] | [] | 1 | treatment_plan |
ONCORX-0062 | The patient was started on Goserelin. | C1_CORE_MED_EXTRACTION | C1.1_single_drug_simple | Easy | [
{
"drug_surface": "Goserelin",
"drug_normalized": "Goserelin",
"status": "current",
"negated": false,
"allergy": false,
"uncertain": false,
"evidence_type": "explicit_surface",
"start_char": 27,
"end_char": 36
}
] | [] | 1 | treatment_plan |
ONCORX-0064 | Home medications include Avelumab. | C1_CORE_MED_EXTRACTION | C1.1_single_drug_simple | Easy | [
{
"drug_surface": "Avelumab",
"drug_normalized": "Avelumab",
"status": "current",
"negated": false,
"allergy": false,
"uncertain": false,
"evidence_type": "explicit_surface",
"start_char": 25,
"end_char": 33
}
] | [] | 1 | oncology_consult |
ONCORX-0065 | Discussed starting Gemcitabine with the patient. | C1_CORE_MED_EXTRACTION | C1.1_single_drug_simple | Easy | [
{
"drug_surface": "Gemcitabine",
"drug_normalized": "Gemcitabine",
"status": "current",
"negated": false,
"allergy": false,
"uncertain": false,
"evidence_type": "explicit_surface",
"start_char": 19,
"end_char": 30
}
] | [] | 1 | oncology_consult |
ONCORX-0066 | Medications: Vinorelbine. | C1_CORE_MED_EXTRACTION | C1.1_single_drug_simple | Easy | [
{
"drug_surface": "Vinorelbine",
"drug_normalized": "Vinorelbine",
"status": "current",
"negated": false,
"allergy": false,
"uncertain": false,
"evidence_type": "explicit_surface",
"start_char": 13,
"end_char": 24
}
] | [] | 1 | progress_note |
ONCORX-0068 | Oncology recommends Procarbazine. | C1_CORE_MED_EXTRACTION | C1.1_single_drug_simple | Easy | [
{
"drug_surface": "Procarbazine",
"drug_normalized": "Procarbazine",
"status": "current",
"negated": false,
"allergy": false,
"uncertain": false,
"evidence_type": "explicit_surface",
"start_char": 20,
"end_char": 32
}
] | [] | 1 | progress_note |
ONCORX-0069 | The patient is scheduled to receive Zanubrutinib. | C1_CORE_MED_EXTRACTION | C1.1_single_drug_simple | Easy | [
{
"drug_surface": "Zanubrutinib",
"drug_normalized": "Zanubrutinib",
"status": "current",
"negated": false,
"allergy": false,
"uncertain": false,
"evidence_type": "explicit_surface",
"start_char": 36,
"end_char": 48
}
] | [] | 1 | progress_note |
ONCORX-0070 | Home medications include Brentuximab Vedotin. | C1_CORE_MED_EXTRACTION | C1.1_single_drug_simple | Easy | [
{
"drug_surface": "Brentuximab Vedotin",
"drug_normalized": "Brentuximab Vedotin",
"status": "current",
"negated": false,
"allergy": false,
"uncertain": false,
"evidence_type": "explicit_surface",
"start_char": 25,
"end_char": 44
}
] | [] | 1 | oncology_consult |
ONCORX-0071 | Home medications include Cetuximab. | C1_CORE_MED_EXTRACTION | C1.1_single_drug_simple | Easy | [
{
"drug_surface": "Cetuximab",
"drug_normalized": "Cetuximab",
"status": "current",
"negated": false,
"allergy": false,
"uncertain": false,
"evidence_type": "explicit_surface",
"start_char": 25,
"end_char": 34
}
] | [] | 1 | treatment_plan |
ONCORX-0073 | Resume Osimertinib after hold period. | C1_CORE_MED_EXTRACTION | C1.1_single_drug_simple | Easy | [
{
"drug_surface": "Osimertinib",
"drug_normalized": "Osimertinib",
"status": "current",
"negated": false,
"allergy": false,
"uncertain": false,
"evidence_type": "explicit_surface",
"start_char": 7,
"end_char": 18
}
] | [] | 1 | progress_note |
ONCORX-0074 | Resume Ixazomib after hold period. | C1_CORE_MED_EXTRACTION | C1.1_single_drug_simple | Easy | [
{
"drug_surface": "Ixazomib",
"drug_normalized": "Ixazomib",
"status": "current",
"negated": false,
"allergy": false,
"uncertain": false,
"evidence_type": "explicit_surface",
"start_char": 7,
"end_char": 15
}
] | [] | 1 | treatment_plan |
ONCORX-0076 | Dasatinib initiated per protocol. | C1_CORE_MED_EXTRACTION | C1.1_single_drug_simple | Easy | [
{
"drug_surface": "Dasatinib",
"drug_normalized": "Dasatinib",
"status": "current",
"negated": false,
"allergy": false,
"uncertain": false,
"evidence_type": "explicit_surface",
"start_char": 0,
"end_char": 9
}
] | [] | 1 | progress_note |
ONCORX-0077 | The patient is scheduled to receive Gemcitabine. | C1_CORE_MED_EXTRACTION | C1.1_single_drug_simple | Easy | [
{
"drug_surface": "Gemcitabine",
"drug_normalized": "Gemcitabine",
"status": "current",
"negated": false,
"allergy": false,
"uncertain": false,
"evidence_type": "explicit_surface",
"start_char": 36,
"end_char": 47
}
] | [] | 1 | oncology_consult |
ONCORX-0079 | Continue Lomustine as previously prescribed. | C1_CORE_MED_EXTRACTION | C1.1_single_drug_simple | Easy | [
{
"drug_surface": "Lomustine",
"drug_normalized": "Lomustine",
"status": "current",
"negated": false,
"allergy": false,
"uncertain": false,
"evidence_type": "explicit_surface",
"start_char": 9,
"end_char": 18
}
] | [] | 1 | progress_note |
ONCORX-0080 | Please continue Polatuzumab Vedotin. | C1_CORE_MED_EXTRACTION | C1.1_single_drug_simple | Easy | [
{
"drug_surface": "Polatuzumab Vedotin",
"drug_normalized": "Polatuzumab Vedotin",
"status": "current",
"negated": false,
"allergy": false,
"uncertain": false,
"evidence_type": "explicit_surface",
"start_char": 16,
"end_char": 35
}
] | [] | 1 | progress_note |
ONCORX-0081 | Patient has been on Ifosfamide since last visit. | C1_CORE_MED_EXTRACTION | C1.1_single_drug_simple | Easy | [
{
"drug_surface": "Ifosfamide",
"drug_normalized": "Ifosfamide",
"status": "current",
"negated": false,
"allergy": false,
"uncertain": false,
"evidence_type": "explicit_surface",
"start_char": 20,
"end_char": 30
}
] | [] | 1 | oncology_consult |
ONCORX-0083 | Recommend initiation of Avelumab. | C1_CORE_MED_EXTRACTION | C1.1_single_drug_simple | Easy | [
{
"drug_surface": "Avelumab",
"drug_normalized": "Avelumab",
"status": "current",
"negated": false,
"allergy": false,
"uncertain": false,
"evidence_type": "explicit_surface",
"start_char": 24,
"end_char": 32
}
] | [] | 1 | progress_note |
ONCORX-0084 | Apalutamide initiated per protocol. | C1_CORE_MED_EXTRACTION | C1.1_single_drug_simple | Easy | [
{
"drug_surface": "Apalutamide",
"drug_normalized": "Apalutamide",
"status": "current",
"negated": false,
"allergy": false,
"uncertain": false,
"evidence_type": "explicit_surface",
"start_char": 0,
"end_char": 11
}
] | [] | 1 | treatment_plan |
ONCORX-0085 | Per oncology, continue Etoposide. | C1_CORE_MED_EXTRACTION | C1.1_single_drug_simple | Easy | [
{
"drug_surface": "Etoposide",
"drug_normalized": "Etoposide",
"status": "current",
"negated": false,
"allergy": false,
"uncertain": false,
"evidence_type": "explicit_surface",
"start_char": 23,
"end_char": 32
}
] | [] | 1 | treatment_plan |
ONCORX-0086 | Will proceed with Brentuximab Vedotin. | C1_CORE_MED_EXTRACTION | C1.1_single_drug_simple | Easy | [
{
"drug_surface": "Brentuximab Vedotin",
"drug_normalized": "Brentuximab Vedotin",
"status": "current",
"negated": false,
"allergy": false,
"uncertain": false,
"evidence_type": "explicit_surface",
"start_char": 18,
"end_char": 37
}
] | [] | 1 | oncology_consult |
ONCORX-0087 | The patient is scheduled to receive Busulfan. | C1_CORE_MED_EXTRACTION | C1.1_single_drug_simple | Easy | [
{
"drug_surface": "Busulfan",
"drug_normalized": "Busulfan",
"status": "current",
"negated": false,
"allergy": false,
"uncertain": false,
"evidence_type": "explicit_surface",
"start_char": 36,
"end_char": 44
}
] | [] | 1 | treatment_plan |
ONCORX-0088 | Patient has been on Atezolizumab since last visit. | C1_CORE_MED_EXTRACTION | C1.1_single_drug_simple | Easy | [
{
"drug_surface": "Atezolizumab",
"drug_normalized": "Atezolizumab",
"status": "current",
"negated": false,
"allergy": false,
"uncertain": false,
"evidence_type": "explicit_surface",
"start_char": 20,
"end_char": 32
}
] | [] | 1 | treatment_plan |
ONCORX-0089 | Active medication: Mitomycin. | C1_CORE_MED_EXTRACTION | C1.1_single_drug_simple | Easy | [
{
"drug_surface": "Mitomycin",
"drug_normalized": "Mitomycin",
"status": "current",
"negated": false,
"allergy": false,
"uncertain": false,
"evidence_type": "explicit_surface",
"start_char": 19,
"end_char": 28
}
] | [] | 1 | oncology_consult |
ONCORX-0090 | Current therapy: Lorlatinib. | C1_CORE_MED_EXTRACTION | C1.1_single_drug_simple | Easy | [
{
"drug_surface": "Lorlatinib",
"drug_normalized": "Lorlatinib",
"status": "current",
"negated": false,
"allergy": false,
"uncertain": false,
"evidence_type": "explicit_surface",
"start_char": 17,
"end_char": 27
}
] | [] | 1 | treatment_plan |
ONCORX-0091 | Medications: Osimertinib. | C1_CORE_MED_EXTRACTION | C1.1_single_drug_simple | Easy | [
{
"drug_surface": "Osimertinib",
"drug_normalized": "Osimertinib",
"status": "current",
"negated": false,
"allergy": false,
"uncertain": false,
"evidence_type": "explicit_surface",
"start_char": 13,
"end_char": 24
}
] | [] | 1 | treatment_plan |
ONCORX-0092 | The patient was started on Sunitinib. | C1_CORE_MED_EXTRACTION | C1.1_single_drug_simple | Easy | [
{
"drug_surface": "Sunitinib",
"drug_normalized": "Sunitinib",
"status": "current",
"negated": false,
"allergy": false,
"uncertain": false,
"evidence_type": "explicit_surface",
"start_char": 27,
"end_char": 36
}
] | [] | 1 | progress_note |
ONCORX-0094 | Please continue Oxaliplatin. | C1_CORE_MED_EXTRACTION | C1.1_single_drug_simple | Easy | [
{
"drug_surface": "Oxaliplatin",
"drug_normalized": "Oxaliplatin",
"status": "current",
"negated": false,
"allergy": false,
"uncertain": false,
"evidence_type": "explicit_surface",
"start_char": 16,
"end_char": 27
}
] | [] | 1 | treatment_plan |
ONCORX-0095 | Please continue Carmustine. | C1_CORE_MED_EXTRACTION | C1.1_single_drug_simple | Easy | [
{
"drug_surface": "Carmustine",
"drug_normalized": "Carmustine",
"status": "current",
"negated": false,
"allergy": false,
"uncertain": false,
"evidence_type": "explicit_surface",
"start_char": 16,
"end_char": 26
}
] | [] | 1 | progress_note |
ONCORX-0097 | Continue Ribociclib as previously prescribed. | C1_CORE_MED_EXTRACTION | C1.1_single_drug_simple | Easy | [
{
"drug_surface": "Ribociclib",
"drug_normalized": "Ribociclib",
"status": "current",
"negated": false,
"allergy": false,
"uncertain": false,
"evidence_type": "explicit_surface",
"start_char": 9,
"end_char": 19
}
] | [] | 1 | progress_note |
ONCORX-0099 | Assessment/Plan: Elotuzumab for treatment. | C1_CORE_MED_EXTRACTION | C1.1_single_drug_simple | Easy | [
{
"drug_surface": "Elotuzumab",
"drug_normalized": "Elotuzumab",
"status": "current",
"negated": false,
"allergy": false,
"uncertain": false,
"evidence_type": "explicit_surface",
"start_char": 17,
"end_char": 27
}
] | [] | 1 | progress_note |
ONCORX-0100 | Patient reports taking Venetoclax at home. | C1_CORE_MED_EXTRACTION | C1.1_single_drug_simple | Easy | [
{
"drug_surface": "Venetoclax",
"drug_normalized": "Venetoclax",
"status": "current",
"negated": false,
"allergy": false,
"uncertain": false,
"evidence_type": "explicit_surface",
"start_char": 23,
"end_char": 33
}
] | [] | 1 | oncology_consult |
ONCORX-0101 | Darolutamide initiated per protocol. | C1_CORE_MED_EXTRACTION | C1.1_single_drug_simple | Easy | [
{
"drug_surface": "Darolutamide",
"drug_normalized": "Darolutamide",
"status": "current",
"negated": false,
"allergy": false,
"uncertain": false,
"evidence_type": "explicit_surface",
"start_char": 0,
"end_char": 12
}
] | [] | 1 | progress_note |
ONCORX-0102 | Recommend initiation of Ixazomib. | C1_CORE_MED_EXTRACTION | C1.1_single_drug_simple | Easy | [
{
"drug_surface": "Ixazomib",
"drug_normalized": "Ixazomib",
"status": "current",
"negated": false,
"allergy": false,
"uncertain": false,
"evidence_type": "explicit_surface",
"start_char": 24,
"end_char": 32
}
] | [] | 1 | treatment_plan |
ONCORX-0104 | Olaparib initiated per protocol. | C1_CORE_MED_EXTRACTION | C1.1_single_drug_simple | Easy | [
{
"drug_surface": "Olaparib",
"drug_normalized": "Olaparib",
"status": "current",
"negated": false,
"allergy": false,
"uncertain": false,
"evidence_type": "explicit_surface",
"start_char": 0,
"end_char": 8
}
] | [] | 1 | progress_note |
ONCORX-0105 | Cemiplimab initiated per protocol. | C1_CORE_MED_EXTRACTION | C1.1_single_drug_simple | Easy | [
{
"drug_surface": "Cemiplimab",
"drug_normalized": "Cemiplimab",
"status": "current",
"negated": false,
"allergy": false,
"uncertain": false,
"evidence_type": "explicit_surface",
"start_char": 0,
"end_char": 10
}
] | [] | 1 | oncology_consult |
ONCORX-0106 | The patient was started on Bleomycin. | C1_CORE_MED_EXTRACTION | C1.1_single_drug_simple | Easy | [
{
"drug_surface": "Bleomycin",
"drug_normalized": "Bleomycin",
"status": "current",
"negated": false,
"allergy": false,
"uncertain": false,
"evidence_type": "explicit_surface",
"start_char": 27,
"end_char": 36
}
] | [] | 1 | progress_note |
ONCORX-0107 | Treatment: Apalutamide. | C1_CORE_MED_EXTRACTION | C1.1_single_drug_simple | Easy | [
{
"drug_surface": "Apalutamide",
"drug_normalized": "Apalutamide",
"status": "current",
"negated": false,
"allergy": false,
"uncertain": false,
"evidence_type": "explicit_surface",
"start_char": 11,
"end_char": 22
}
] | [] | 1 | oncology_consult |
ONCORX-0108 | Treatment: Trametinib. | C1_CORE_MED_EXTRACTION | C1.1_single_drug_simple | Easy | [
{
"drug_surface": "Trametinib",
"drug_normalized": "Trametinib",
"status": "current",
"negated": false,
"allergy": false,
"uncertain": false,
"evidence_type": "explicit_surface",
"start_char": 11,
"end_char": 21
}
] | [] | 1 | oncology_consult |
ONCORX-0109 | Patient has been on Elotuzumab since last visit. | C1_CORE_MED_EXTRACTION | C1.1_single_drug_simple | Easy | [
{
"drug_surface": "Elotuzumab",
"drug_normalized": "Elotuzumab",
"status": "current",
"negated": false,
"allergy": false,
"uncertain": false,
"evidence_type": "explicit_surface",
"start_char": 20,
"end_char": 30
}
] | [] | 1 | progress_note |
ONCORX-0110 | Home medications include Tamoxifen. | C1_CORE_MED_EXTRACTION | C1.1_single_drug_simple | Easy | [
{
"drug_surface": "Tamoxifen",
"drug_normalized": "Tamoxifen",
"status": "current",
"negated": false,
"allergy": false,
"uncertain": false,
"evidence_type": "explicit_surface",
"start_char": 25,
"end_char": 34
}
] | [] | 1 | treatment_plan |
ONCORX-0111 | Continue Fluorouracil as previously prescribed. | C1_CORE_MED_EXTRACTION | C1.1_single_drug_simple | Easy | [
{
"drug_surface": "Fluorouracil",
"drug_normalized": "Fluorouracil",
"status": "current",
"negated": false,
"allergy": false,
"uncertain": false,
"evidence_type": "explicit_surface",
"start_char": 9,
"end_char": 21
}
] | [] | 1 | oncology_consult |
ONCORX-0112 | Assessment/Plan: Degarelix for treatment. | C1_CORE_MED_EXTRACTION | C1.1_single_drug_simple | Easy | [
{
"drug_surface": "Degarelix",
"drug_normalized": "Degarelix",
"status": "current",
"negated": false,
"allergy": false,
"uncertain": false,
"evidence_type": "explicit_surface",
"start_char": 17,
"end_char": 26
}
] | [] | 1 | progress_note |
ONCORX-0114 | Medications: Carfilzomib. | C1_CORE_MED_EXTRACTION | C1.1_single_drug_simple | Easy | [
{
"drug_surface": "Carfilzomib",
"drug_normalized": "Carfilzomib",
"status": "current",
"negated": false,
"allergy": false,
"uncertain": false,
"evidence_type": "explicit_surface",
"start_char": 13,
"end_char": 24
}
] | [] | 1 | progress_note |
ONCORX-0115 | Trametinib was administered during today's visit. | C1_CORE_MED_EXTRACTION | C1.1_single_drug_simple | Easy | [
{
"drug_surface": "Trametinib",
"drug_normalized": "Trametinib",
"status": "current",
"negated": false,
"allergy": false,
"uncertain": false,
"evidence_type": "explicit_surface",
"start_char": 0,
"end_char": 10
}
] | [] | 1 | oncology_consult |
ONCORX-0116 | Patient reports taking Axitinib at home. | C1_CORE_MED_EXTRACTION | C1.1_single_drug_simple | Easy | [
{
"drug_surface": "Axitinib",
"drug_normalized": "Axitinib",
"status": "current",
"negated": false,
"allergy": false,
"uncertain": false,
"evidence_type": "explicit_surface",
"start_char": 23,
"end_char": 31
}
] | [] | 1 | progress_note |
ONCORX-0117 | Initiate therapy with Sorafenib as discussed. | C1_CORE_MED_EXTRACTION | C1.1_single_drug_simple | Easy | [
{
"drug_surface": "Sorafenib",
"drug_normalized": "Sorafenib",
"status": "current",
"negated": false,
"allergy": false,
"uncertain": false,
"evidence_type": "explicit_surface",
"start_char": 22,
"end_char": 31
}
] | [] | 1 | treatment_plan |
ONCORX-0119 | The patient is scheduled to receive Bendamustine. | C1_CORE_MED_EXTRACTION | C1.1_single_drug_simple | Easy | [
{
"drug_surface": "Bendamustine",
"drug_normalized": "Bendamustine",
"status": "current",
"negated": false,
"allergy": false,
"uncertain": false,
"evidence_type": "explicit_surface",
"start_char": 36,
"end_char": 48
}
] | [] | 1 | progress_note |
ONCORX-0120 | Treatment: Etoposide. | C1_CORE_MED_EXTRACTION | C1.1_single_drug_simple | Easy | [
{
"drug_surface": "Etoposide",
"drug_normalized": "Etoposide",
"status": "current",
"negated": false,
"allergy": false,
"uncertain": false,
"evidence_type": "explicit_surface",
"start_char": 11,
"end_char": 20
}
] | [] | 1 | oncology_consult |
ONCORX-0122 | Continue Methylprednisolone as previously prescribed. | C1_CORE_MED_EXTRACTION | C1.1_single_drug_simple | Easy | [
{
"drug_surface": "Methylprednisolone",
"drug_normalized": "Methylprednisolone",
"status": "current",
"negated": false,
"allergy": false,
"uncertain": false,
"evidence_type": "explicit_surface",
"start_char": 9,
"end_char": 27
}
] | [] | 1 | progress_note |
ONCORX-0124 | The patient is scheduled to receive Procarbazine. | C1_CORE_MED_EXTRACTION | C1.1_single_drug_simple | Easy | [
{
"drug_surface": "Procarbazine",
"drug_normalized": "Procarbazine",
"status": "current",
"negated": false,
"allergy": false,
"uncertain": false,
"evidence_type": "explicit_surface",
"start_char": 36,
"end_char": 48
}
] | [] | 1 | oncology_consult |
ONCORX-0125 | Treatment: Thioguanine. | C1_CORE_MED_EXTRACTION | C1.1_single_drug_simple | Easy | [
{
"drug_surface": "Thioguanine",
"drug_normalized": "Thioguanine",
"status": "current",
"negated": false,
"allergy": false,
"uncertain": false,
"evidence_type": "explicit_surface",
"start_char": 11,
"end_char": 22
}
] | [] | 1 | treatment_plan |
ONCORX-0126 | Initiate therapy with Degarelix as discussed. | C1_CORE_MED_EXTRACTION | C1.1_single_drug_simple | Easy | [
{
"drug_surface": "Degarelix",
"drug_normalized": "Degarelix",
"status": "current",
"negated": false,
"allergy": false,
"uncertain": false,
"evidence_type": "explicit_surface",
"start_char": 22,
"end_char": 31
}
] | [] | 1 | treatment_plan |
ONCORX-0127 | Active medication: Apalutamide. | C1_CORE_MED_EXTRACTION | C1.1_single_drug_simple | Easy | [
{
"drug_surface": "Apalutamide",
"drug_normalized": "Apalutamide",
"status": "current",
"negated": false,
"allergy": false,
"uncertain": false,
"evidence_type": "explicit_surface",
"start_char": 19,
"end_char": 30
}
] | [] | 1 | oncology_consult |
OncoRx-Bench
OncoRx-Bench is a controlled synthetic dataset for research on medication and oncology-regimen information extraction. The reference release contains 2,000 automatically generated records: 1,600 training rows and 400 test rows. Whole source-template groups are assigned to one split, yielding zero source-template overlap while preserving an exact 80/20 split within every subcategory.
The text and task-selected annotations are synthetic. Automated validation establishes structural, referential, offset, evidence, distribution, and split consistency; it does not establish clinical validity. The dataset is not for clinical use, clinical decision-making, prescribing, or patient care.
Links
- Source and reproducibility workflow: https://github.com/shivanna-ornl/oncorx-bench
- Dataset page: https://huggingface.co/datasets/AbhishekShivanna/oncorx-bench
- Knowledge source: https://github.com/shivanna-ornl/unified-oncology-treatment-database
Data files
| Split | Path | Rows |
|---|---|---|
| train | data/train.jsonl |
1,600 |
| test | data/test.jsonl |
400 |
The split union contains exactly ONCORX-0001 through ONCORX-2000, with no
duplicate identifiers and no overlap. The canonical full JSONL SHA-256 is
97a6c2a22eacf0d68e1762051fbe57b943f24c032a014eadd64f7e36aecf952f.
from datasets import load_dataset
dataset = load_dataset("AbhishekShivanna/oncorx-bench")
print(dataset["train"][0])
Schema
| Field | Type | Description |
|---|---|---|
sample_id |
string | Record identifier |
clinical_text |
string | Synthetic input text |
category |
string | Major evaluation category |
subcategory |
string | Fine-grained evaluation category |
difficulty |
string | Author-assigned scenario difficulty |
drug_mentions |
list of objects | Drug evidence spans, normalized labels, context, and optional prescribing attributes |
regimen_mentions |
list of objects | Regimen evidence spans, normalized labels, projected components, and visible cycle/intent metadata |
num_drugs |
integer | Number of unique normalized drugs in drug_mentions |
note_type |
string | Scenario-conditioned synthetic note-type metadata |
Drug objects include inclusive start_char and exclusive end_char offsets.
The evidence_type field distinguishes a literal explicit_surface from a
regimen_inference, for which the stored evidence span is the named regimen.
Optional fields are omitted when they are not supported by the rendered text.
Reference-release composition
- 3,525 drug annotation objects, including 2,974 explicit-surface objects and 551 regimen-inference objects
- 170 unique normalized drugs and 433 stored evidence surfaces: 328 literal drug surfaces and 105 regimen-evidence spans
- 1,286 drug objects with prescribing information
- 444 regimen objects spanning 176 normalized regimen names
- 1,110 component assignments spanning 109 unique components
| Category | Description | Rows |
|---|---|---|
| C1 | Core medication extraction | 600 |
| C2 | Prescribing information | 450 |
| C3 | Regimen semantics | 450 |
| C4 | Context and safety language | 300 |
| C5 | Noise and ambiguity | 200 |
Provenance and reproducibility
The generator consumes three checked-in benchmark views derived by a checksum-verifying adapter from a pinned Unified Oncology Treatment Database revision. The source repository contains the materialized inputs, projection audit, provenance manifest, generator, strict validator, deterministic split exporter, tests, and one-command byte-comparison workflow.
This Hugging Face repository intentionally contains only the dataset card and Viewer-compatible split files. Benchmark generation and validation code lives in the linked GitHub repository.
Limitations
- Records are short English template-generated snippets, not real clinical notes, and they do not model full documents or EHR prevalence.
- No independent clinical adjudication was performed. Knowledge grounding and structural validation do not prove the appropriateness of every disease, drug, dose, route, frequency, schedule, or regimen combination.
- Annotations are task-selected rather than guaranteed exhaustive for every medication-like string in every category.
- The provided split is source-template-disjoint but not drug-, entity-, or regimen-disjoint.
- Author-controlled attribute profiles and surface-variation maps are synthetic benchmark controls, not treatment recommendations.
License and redistribution
No license is declared for this dataset release. Public availability does not supersede the terms of the source knowledge resources. Review the data notice and provenance in the linked GitHub repository before redistribution or commercial use.
Citation
Until the paper is published, cite this dataset repository and the exact Hub revision used. Use the linked GitHub repository for the corresponding source revision and reproduction instructions.
- Downloads last month
- 17